{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:27:49Z","timestamp":1794587269409,"version":"4.9.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Etrasimod, a newly approved oral sphingosine-1-phosphate receptor modulator, treats moderate-to-severe ulcerative colitis (UC) by inhibiting lymphocyte migration and reducing intestinal inflammation. This meta-analysis evaluates its efficacy and safety to strengthen evidence for clinical decision-making in UC management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>PubMed, Scopus, and Web of Science servers were used to conduct a systematic search in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The meta-analysis of pooled effect estimates is produced using Review Manager and R software. A random-effects model was used. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach and publication bias through funnel plots and Egger test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 2 studies (3 randomized controlled trials) comprising 943 participants were included in this analysis. Pooled effect estimates demonstrated that etrasimod significantly improved clinical response, endoscopic improvement, clinical remission, and histological remission. The most commonly reported adverse events were UC worsening or flare (5.73%), headache (5.26%), anemia (3.57%), pyrexia (2.96%), and arthralgia (2.42%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Overall, etrasimod therapy demonstrates a favorable benefit-to-risk profile, with its therapeutic advantages outweighing the likelihood of associated side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049370","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:00:43Z","timestamp":1782108043000},"page":"e49370","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of etrasimod in ulcerative colitis: Evidence from a meta-analysis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4234-6141","authenticated-orcid":false,"given":"Deekshitha","family":"Alla","sequence":"first","affiliation":[{"name":"Andhra Medical College, Visakhapatnam, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7863-8077","authenticated-orcid":false,"given":"Srinidhi","family":"Appala","sequence":"additional","affiliation":[{"name":"All India Institute of Medical Sciences Bhopal, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4773-0133","authenticated-orcid":false,"given":"Shourya","family":"Meyur","sequence":"additional","affiliation":[{"name":"Texas Tech University of Health Sciences, Lubbock, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2843-1513","authenticated-orcid":false,"given":"Sri Lakshmi","family":"Ganguru","sequence":"additional","affiliation":[{"name":"NRI Medical College and General Hospital, Guntur, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9447-3391","authenticated-orcid":false,"given":"Rakshna","family":"Ramsundar","sequence":"additional","affiliation":[{"name":"Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0761-4694","authenticated-orcid":false,"given":"Sanjana","family":"Gupta","sequence":"additional","affiliation":[{"name":"Geetanjali Medical College and Hospital, Udaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1730-5472","authenticated-orcid":false,"given":"Praneeth Koushik","family":"Sriramaneni","sequence":"additional","affiliation":[{"name":"Kamineni Academy of Medical Sciences and Research Center, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0573-3395","authenticated-orcid":false,"given":"Gitanjali","family":"Boppana","sequence":"additional","affiliation":[{"name":"Andhra Medical College, Visakhapatnam, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8795-9360","authenticated-orcid":false,"given":"Sridevi Ravi","family":"Cheguru","sequence":"additional","affiliation":[{"name":"JJM Medical College, Davangere, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2488-0781","authenticated-orcid":false,"given":"Nyassiri Warai","family":"Emmanuel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Biomedical Sciences, University of Garoua, Garoua, North Region, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3487-2428","authenticated-orcid":false,"given":"Madhumitha","family":"Bolineni","sequence":"additional","affiliation":[{"name":"Andhra Medical College, Visakhapatnam, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1317-7853","authenticated-orcid":false,"given":"Ritvik Prakash","family":"Rohan","sequence":"additional","affiliation":[{"name":"JJM Medical College, Davangere, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Chowdhary","sequence":"additional","affiliation":[{"name":"Combined Internal Medicine-Paediatrics Residency Metrohealth System\/Case Western Reserve University Program, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261113","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.3748\/wjg.v20.i28.9458","article-title":"Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis.","volume":"20","author":"Da Silva","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R2-20261113","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis.","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet"},{"key":"R3-20261113","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.10.035","article-title":"Colorectal cancer in Inflammatory bowel disease: mechanisms and management.","volume":"162","author":"Shah","year":"2022","journal-title":"Gastroenterology"},{"key":"R4-20261113","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis.","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"R5-20261113","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults.","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"R6-20261113","first-page":"406","article-title":"Ulcerative colitis: rapid evidence review.","volume":"105","author":"Adams","year":"2022","journal-title":"Am Fam Physician"},{"key":"R7-20261113","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/ecco-jcc\/jjad100","article-title":"Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis.","volume":"17","author":"Solitano","year":"2023","journal-title":"J Crohns Colitis"},{"key":"R8-20261113","doi-asserted-by":"crossref","first-page":"502363","DOI":"10.1016\/j.gastrohep.2025.502363","article-title":"Etrasimod: review of the efficacy and therapeutic prospects of a new oral therapy for the treatment of ulcerative colitis [Etrasimod: revisi\u00f3n de la eficacia y las perspectivas terap\u00e9uticas de una nueva terapia oral para el tratamiento de la colitis ulcerosa].","volume":"48","author":"Gisbert","year":"2025","journal-title":"Gastroenterol Hepatol"},{"key":"R9-20261113","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (Elevate): two randomised, double-blind, placebo-controlled, phase 3 studies.","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"R10-20261113","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis.","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"R11-20261113","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study.","volume":"15","author":"Vermeire","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R13-20261113","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ecco-jcc\/jjae038","article-title":"Efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis: results from the phase 3 Elevate UC clinical programme.","volume":"18","author":"Peyrin-Biroulet","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R14-20261113","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-020-01431-8","article-title":"Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects.","volume":"81","author":"Chun","year":"2021","journal-title":"Drugs"},{"key":"R15-20261113","first-page":"265","article-title":"Sphingosine-1 phosphate receptor modulators: the next wave of oral therapies in inflammatory bowel disease.","volume":"18","author":"Choden","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R16-20261113","doi-asserted-by":"crossref","first-page":"1420455","DOI":"10.3389\/fphar.2024.1420455","article-title":"Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials.","volume":"15","author":"Qiu","year":"2024","journal-title":"Front Pharmacol"},{"key":"R17-20261113","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000518131","article-title":"Assessment of endoscopic disease activity in ulcerative colitis: is simplicity the ultimate sophistication?","volume":"7","author":"Sharara","year":"2022","journal-title":"Inflamm Intest Dis"},{"key":"R18-20261113","first-page":"888","article-title":"Efficacy and safety of etrasimod in ulcerative colitis: results from the Elevate UC 52 and UC 12 trials.","volume":"388","author":"Sandborn","year":"2023","journal-title":"N Engl J Med"},{"key":"R19-20261113","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.3390\/jcm12155014","article-title":"Efficacy and safety of S1P1 receptor modulator drugs for patients with moderate-to-severe ulcerative colitis.","volume":"12","author":"Bencardino","year":"2023","journal-title":"J Clin Med"},{"key":"R20-20261113","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000541383","article-title":"Efficacy and safety of etrasimod in patients with ulcerative colitis in Japan: data from the phase 3 Elevate UC 12 and Elevate UC 40 JAPAN trials.","volume":"106","author":"Takeuchi","year":"2025","journal-title":"Digestion"},{"key":"R21-20261113","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/CEG.S391706","article-title":"Therapeutic potential of etrasimod in the management of moderately-to-severely active ulcerative colitis: evidence to date.","volume":"17","author":"Glassner","year":"2024","journal-title":"Clin Exp Gastroenterol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:01:24Z","timestamp":1794585684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":20,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049370","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"2025-09-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}